KYTX earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -2.26. Updated 2026-07-23.
Kyverna Therapeutics (KYTX) Research Hub
Kyverna Therapeutics (KYTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.26 USD (-4.97%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.26, market cap 0.32B. This hub links to the full technical, earnings and options research available for KYTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.26 USD (-4.97%) |
| 52-week range | 6.98 USD – 10.19 USD |
| Trend regime | Range |
| 14-day RSI | 40.1 (Bearish) |
| Trailing P/E | -2.26 |
| Market cap | 0.32B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for KYTX
Covered Call on KYTX: how it works, illustrative setup around the real 7.26 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KYTX: how it works, illustrative setup around the real 7.26 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KYTX: how it works, illustrative setup around the real 7.26 USD price, max profit/loss, breakeven and when to use it. Educational.
KYTX technical analysis: range, last 7.26 USD, RSI 40.1, 52w range 6.98 USD–10.19 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KYTX in?
Kyverna Therapeutics (KYTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KYTX in an uptrend or downtrend?
As of 2026-09-11, KYTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KYTX's trailing P/E ratio?
KYTX's trailing P/E is -2.26, with a market cap of 0.32B. See the earnings research page for full valuation detail.
When does KYTX next report earnings?
KYTX is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.67 USD.